Aliskiren–hydrochlorothiazide combination for the treatment of hypertension

References

• Ong KL, Cheung BM, Man YB, Lau CP, Lan KS. Prevalence, awareness, treatment and control of hypertension among United States adults 1999–2004. Hypertension49, 69–75 (2007).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med.328, 914–921 (1993).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens.4, 393–404 (2002).
   PubMedGoogle Scholar
• Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch. Intern. Med.154, 737–743 (1994).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens.17, 252–259 (2003).
   Web of Science ®Google Scholar
• Tiegerstedt R, Bergman PG. Niere und Kreislaub. Skandinävisches Archiv für Physiologie8, 223–271 (1898).
   Google Scholar
• Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now and where are we going? J. Hypertens.24, 243–256 (2006).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Re RN. Do we need yet another blocker of the renin–angiotensin system? J. Am. Coll. Cardiol.49, 1164–1165 (2007).
   PubMed Web of Science ®Google Scholar
• Sealey JE, Laragh JH. Aliskiren, first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am. J. Hypertens.20, 587–597 (2007).
   PubMed Web of Science ®Google Scholar
• Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol.1, 221–228 (2006).
   PubMed Web of Science ®Google Scholar
• Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun.308, 698–705 (2003).
   PubMed Web of Science ®Google Scholar
• Waldmeir FJ, Glaeznel U, Wirz B et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab. Dispos.35, 1418–1428 (2007).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jermany J, Yeh CM, Bizot M-N, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br. J. Clin. Pharmacol.62, 690–698 (2006).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S. Warren V, Yeh CM, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J. Clin. Pharmacol.47, 192–200 (2007).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Bigler H, Yeh CM et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin. Pharmacokinet.46, 661–675 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker. Hypertension49, 276–284 (2007).
   PubMed Web of Science ®Google Scholar
• Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens.23, 417–426 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Dieterich HA. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with Type II diabetes mellitus. Clin. Pharmacokinet.45, 1125–1134 (2006).
   PubMed Web of Science ®Google Scholar
• Viadyanathan S, Reynolds C, Yeh CM et al. Pharmacokinetics, safety and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J. Clin. Pharmacol.47, 453–460 (2007).
   PubMed Web of Science ®Google Scholar
• Danser AHJ, Deinum J. Renin, pro-renin, and the putative (pro) renin receptor. Hypertension46, 1069–1076 (2005).
   PubMed Web of Science ®Google Scholar
• Sepehrdad R, Frishman WH, Stier CT, Sica DA. Direct inhibition of renin as a cardiovascular pharmacotherapy focus on aliskiren. Cardiol. Rev.15, 242–256 (2007).
   PubMedGoogle Scholar
• Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of the renin/pro-renin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest.109, 1417–1427 (2002).
   PubMed Web of Science ®Google Scholar
• Van Kasteren CAM, Danser AHJ, Derkx FHM et al. Manose-6-phosphate receptor-mediated internalization and activation of pro-renin by cardiac cells. Hypertension30, 1389–1396 (1997).
   PubMed Web of Science ®Google Scholar
• Vandeneunden MMED, Saris JJ, deBruin RJA et al. Pro-renin accumulation and activation in human endothelial cells. Importance of manose-6-phosphate receptors. Arterioscler. Thromb. Vasc. Biol.21, 911–916 (2001).
   PubMed Web of Science ®Google Scholar
• Nguyen G, Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Curr. Opin. Pharmacol. Epub ahead of print (2008).
   PubMedGoogle Scholar
• Menard J, Guyene TT, Chatellier G, Kleinbloessen CH, Bernadet P. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension18, 257–265 (1991).
   PubMed Web of Science ®Google Scholar
• Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension46, 569–576 (2005).
   PubMed Web of Science ®Google Scholar
• Nussberger J, Wuerzner G, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension39, E1–E8 (2002).
   PubMed Web of Science ®Google Scholar
• Azizi M, Menard J, Bissery A, Guyenne TT, Vaidyanathan S, Camisasca RP. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol.15, 3126–3133 (2004).
   PubMed Web of Science ®Google Scholar
• Frampton JE, Curran MP. Aliskiren: A review of its use in the management of hypertension. Drugs67, 1767–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br. J. Clin. Pharmacol.58, 433–436 (2004).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Valencia J, Kemp C et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract.60, 1343–1356 (2006).
   PubMed Web of Science ®Google Scholar
• Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharmocol. Ther.43, 527–535 (2005).
   PubMed Web of Science ®Google Scholar
• Kushiro T, Itakura H, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens. Res.29, 997–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol.49, 1157–1163 (2007).
   PubMed Web of Science ®Google Scholar
• Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens.25, 217–226 (2007).
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Boye SW, Lebreton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension49, 1047–1055 (2007).
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with the oral renin inhibitor, aliskiren. Hypertension42, 1137–1143 (2003).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation111, 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am. J. Hypertens.20, 11–20 (2007).
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined-use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet370, 221–229 (2007).
   PubMed Web of Science ®Google Scholar
• Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension45, 880–886 (2005).
   PubMed Web of Science ®Google Scholar
• Menard J, Azizi M. The difficult conception, birth and delivery of renin inhibitor: controversies around aliskiren. J. Hypertens.25, 1775–1782 (2007).
   PubMed Web of Science ®Google Scholar
• Schmieder RE. The potential role of prorenin in diabetic nephropathy. J. Hypertens.25, 1323–2328 (2007).
   PubMed Web of Science ®Google Scholar
• Ganten D, Wagner J, Bader M et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc. Natl Acad. Sci. USA89, 7806–7810 (1992).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ichihara A, Kaneshiro Y et al. Regression of nephropathy developed in diabetes by (pro) renin receptor blockade. J. Am. Soc. Nephrol.18, 2054–2061 (2007).
   PubMed Web of Science ®Google Scholar
• Birkenhager WH, Staessen JA. Dual inhibition of the renin system by aliskiren and valsartan. Lancet370, 195–196 (2007).
   PubMed Web of Science ®Google Scholar
• Bühler FR, Laragh JH, Baer L, Vaughan ED Jr, Burnner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypotensive diseases. N. Engl. J. Med.287, 1209–1214 (1972).
   PubMed Web of Science ®Google Scholar
• Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens.12, 451–459 (1999).
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today40, 791–801 (2004).
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J. Hum. Hypertens.19, 923–931 (2005).
   PubMed Web of Science ®Google Scholar
• Victor RG. Pathophysiology of target-organ disease. Does angiotensin II remain the key? J. Clin. Hypertens.9(Suppl. 4), 4–10 (2007).
   PubMedGoogle Scholar
• Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). Expert Rev. Cardiovasc. Ther.1(3), 335–343 (2003).
   PubMedGoogle Scholar